Lördag 7 Juni | 11:32:07 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-12 07:00 Kvartalsrapport 2025-Q3
2025-08-20 07:00 Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamma inom medicinteknik. Idag är bolaget specialiserade inom forskning och utveckling av diabetes. Produkterna är patenterade och används som glukosgivare. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.
2025-06-05 12:52:00

Reference is made to the stock exchange announcement by Lifecare ASA (the "Company") dated 2 June 2025 regarding the commencement of the exercise period for 4,193,806 warrants (the "Warrants") issued in connection with the partially underwritten rights issue of new shares in the Company completed in June 2024 (the "Rights Issue").

Each Warrant gives the holder a right to subscribe for one new share in the Company at an exercise price per share of NOK 5.31681. The Warrants are listed and tradable on Euronext Oslo Stock Exchange under the ticker code "LIFES". Warrants that are not exercised to subscribe for new shares before the end of the Exercise Period at 16:30 hours (CEST) on 13 June 2025 or sold before 16:30 hours (CEST) on 6 June 2025 will have no value and will lapse without compensation to the holder. Holders of Warrants who do not exercise their Warrants within the Exercise Period may experience a dilution of their shareholding in the Company.

The Company has been informed that Teigland AS, a company closely related to Trine Teigland, Board member and primary insider of Lifecare ASA, has exercised 100,922 Warrants, for the allocation of 100,922 New Shares in the Company at a price per New Share of NOK 5.31681.

Please see details about the transaction in the attached form.

Subject to timely payment of the aggregate exercise amount for the new shares on 19 June 2025, the Company expects that the share capital increase pertaining to the issuance of the new shares will be registered with the Norwegian Register of Business Enterprises on or about 24 June 2025 and that shares will be delivered to the VPS accounts of the subscribers to whom they are allocated on or about 25 June 2025.

The shares received upon exercise of Warrants will be listed on Euronext Oslo Børs under ISIN NO0013355859 and ticker code "LIFE". The shares will be listed as soon as the new shares are fully paid, the share capital increase pertaining to the issuance of the new shares has been registered in the Norwegian Register of Business Enterprises, and the new shares have been issued in the VPS.

The shares received upon exercise of Warrants may not be transferred or traded before (i) the new shares have been fully paid, (ii) the share capital increase pertaining to the issuance of the new shares has been registered with the Norwegian Register of Business Enterprises, and (iii) the new shares have been issued in the VPS.